Polycystic Ovarian Syndrome - Drug Pipeline Landscape, 2023

Polycystic Ovarian Syndrome - Drug Pipeline Landscape, 2023

Polycystic Ovarian Syndrome (PCOS) is a metabolic disorder which causes hormonal imbalance in women and tends to increase level of male hormones leads to erratic menstrual cycles, missed periods and irregular ovulation, abnormal hair growth on the body and face simultaneously it can lead to heart disease and diabetes in long term. Small cysts may develop on the ovaries (fluid-filled sacs) due to lack of ovulation (anovulation). However, despite the name "polycystic," one does not need to have cysts on ovaries to have PCOS.

The most common causes of Polycystic Ovarian Syndrome are genetics, higher male hormone (androgen) levels, insulin resistance, low-grade inflammation, obesity.

The most common symptoms of Polycystic Ovarian Syndrome include irregular periods or no periods, heavy menstrual bleeding, difficulty getting pregnant, excessive hair growth on the face, chest, back or buttocks, hair loss, acne.

Polycystic Ovarian Syndrome can be diagnosed by the doctors by discussion of your symptoms, menstrual periods and any weight changes and physical pelvic exam including blood tests and ultrasound/imaging tests.

The most common treatments for Polycystic Ovarian Syndrome are medications such as combination birth control pills, progestin therapy, or Clomiphene, Letrozole, Gonadotropins, lifestyle changes such as change in diet and activity.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Polycystic ovarian syndrome treatment such as Corifollitropin Alfa, Elagolix, Saroglitazar and others. Key players involved in the development of therapies to treat polycystic ovarian syndrome are Merck Sharp & Dohme LLC, AbbVie, Zydus Lifesciences Ltd, Spruce Biosciences, PT. Prodia Stem Cell Indonesia and others. One drug is under late-stage Phase III clinical trials, four drugs are in Phase II clinical trials and some other drugs are under preclinical stages of development.

Report Highlights

Global Insight Service's, Polycystic Ovarian Syndrome - Drug Pipeline Landscape, 2023 report provides an overview of the Polycystic Ovarian Syndrome pipeline drugs. This report covers detailed insights on Polycystic Ovarian Syndrome drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Polycystic Ovarian Syndrome pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

1. Introduction
1.1 Polycystic Ovarian Syndrome - Pipeline Drugs, 2023 - Coverage
2. Disease Overview - Polycystic Ovarian Syndrome
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3. Polycystic Ovarian Syndrome - Pipeline Drugs Development - Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2023
3.3 Products under Development by Companies, 2023
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration
5. Drug Profiles
5.1 Clinical Stage Drugs - Phase III
5.1.1. Corifollitropin Alfa
5.2 Clinical Stage Drugs - Phase II
5.2.1 Elagolix
5.2.2 Saroglitazar
5.2.3 Tildacerfont
5.2.4 Umbilical Cord Mesenchymal Stem Cells and Secretoms
5.3 Early-Stage Drugs - Preclinical
5.3.1 AMTX-036
5.3.2 HSD17B5 Inhibitor
5.3.3 RK-01
5.3.4 Thermostem
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 AbbVie
9.2 Amaro Therapeutics
9.3 Arkay Therapeutics LLC
9.4 BioRestorative Therapies Inc
9.5 Merck Sharp & Dohme LLC
9.6 Organon
9.7 PT. Prodia Stem Cell Indonesia
9.8 Spruce Biosciences
9.9 Zydus Lifesciences Ltd
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
11. Appendix
List of Tables
Table 1.1 Number of Products under Development by Polycystic Ovarian Syndrome
Table 1.2 Number of Products under Development by Companies
Table 1.3 Products under Development by Companies
Table 1.4 Products by Targets
Table 1.5 Products by Mechanism of Action
Table 1.6 Products by Molecule Type
Table 1.7 Products by Route of Administration
Table 2.1 Clinical Trial Details - Corifollitropin Alfa/Merck Sharp & Dohme LLC
Table 2.2 Clinical Trial Details - Elagolix/AbbVie
Table 2.3 Clinical Trial Details - Saroglitazar/Zydus Lifesciences Ltd
Table 2.4 Clinical Trial Details - Tildacerfont/Spruce Biosciences
Table 2.5 Clinical Trial Details - Umbilical Cord Mesenchymal Stem Cells and Secretoms/PT. Prodia Stem Cell Indonesia
Table 3.1 Regulatory Designations
Table 4.2 Inactive Drugs
Table 4.2 Discontinued Drugs
List of Figures
Figure 1.1 Number of Products under Development for Polycystic Ovarian Syndrome, 2023
Figure 1.2 Products by Top 5 Targets and Stage of Development for Polycystic Ovarian Syndrome, 2023
Figure 1.3 Products by Top 5 Mechanism of Action for Polycystic Ovarian Syndrome, 2023
Figure 1.4 Products by Top 5 Molecule Type for Polycystic Ovarian Syndrome, 2023
Figure 1.5 Products by Top 5 Route of Administration for Polycystic Ovarian Syndrome, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings